Clinical Trials Logo

Filter by:
NCT ID: NCT02891226 Completed - Crohn's Disease Clinical Trials

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

SERENITY
Start date: December 14, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

NCT ID: NCT02890524 Completed - Aphthous Stomatitis Clinical Trials

Tokushima Night Guard for Recurrent Aphthous Stomatitis

Start date: July 2014
Phase: N/A
Study type: Interventional

The investigators will investigate whether the night guard can suppress the development of recurrent aphthous stomatitis (RAS). The investigators will record the patients' oral condition for 60 days before and after intervention with the night guard made of Ethylene-Vinyl Acetate copolymer (EVA). The patients' saliva will be analyzed for measurement of inflammatory cytokines or oxidative stress.

NCT ID: NCT02890173 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 in Patients With Essential Hypertension

ESAX-HTN
Start date: September 2016
Phase: Phase 3
Study type: Interventional

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.

NCT ID: NCT02889796 Completed - Clinical trials for Rheumatoid Arthritis

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

FINCH 1
Start date: August 30, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

NCT ID: NCT02889653 Completed - Clinical trials for Cerebrovascular and Cardiovascular Diseases

The Bleeding With Antithrombotic Therapy Study 2

BAT2
Start date: October 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.

NCT ID: NCT02889302 Completed - Clinical trials for Spinocerebellar Degeneration

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Start date: November 15, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients.

NCT ID: NCT02888210 Completed - Cataract Clinical Trials

A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Start date: September 3, 2016
Phase: Phase 3
Study type: Interventional

To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes

NCT ID: NCT02886728 Completed - Clinical trials for Rheumatoid Arthritis

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

FINCH 3
Start date: August 8, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).

NCT ID: NCT02885662 Completed - Clinical trials for Primary Aldosteronism

Study of CS-3150 in Patients With Primary Aldosteronism

Start date: September 2016
Phase: N/A
Study type: Interventional

To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.

NCT ID: NCT02884726 Completed - Advanced Cancer Clinical Trials

Phase 1 Study of Mesothelin-ADC

Start date: October 14, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in subjects with advanced and/or metastatic solid tumors.